Psilocybin Therapy Drives 75% PTSD Remission

 Will your competent? doctor go through all the headaches of approvals for your PTSD or do the correct option? EXACT 100% RECOVERY PROTOCOLS!

Since there is a 23% chance of stroke survivors getting PTSD what is your doctor's prevention plan?

Of course your competent? doctor ignored all the previous positive research on psilocybin for stroke! Over a decade of incompetence!

psilocybin (57 posts to May 2014) 

The latest here:

Psilocybin Therapy Drives 75% PTSD Remission

Summary: The first U.S. clinical trial evaluating psilocybin-assisted therapy in military veterans with treatment-resistant post-traumatic stress disorder (PTSD) has demonstrated significant safety and clinical efficacy.

The 11-week pilot trial combined 14 to 16 hours of preparation and integration psychotherapy with two synthetic psilocybin dosing sessions (15 mg and 25 mg). One month post-treatment, 75% of participants (9 of 12) achieved full PTSD remission, with an average clinician-rated symptom score reduction of 27.5 points.

The protocol produced no serious adverse events, no increase in suicidal ideation, and demonstrated that non-drug psychotherapy acts as an essential substrate that psilocybin catalyzes to achieve durable therapeutic breakthroughs.

Key Facts

• High Remission Efficacy: 75% of trial participants (9 out of 12 veterans with severe treatment-resistant PTSD) no longer met diagnostic criteria for PTSD one month after treatment completion.
• Symptom Reduction Magnitude: Clinician-administered assessment scales revealed a mean decrease of 27.5 points in overall PTSD symptom severity from baseline to one month post-treatment.
• Favorable Safety Profile: No serious adverse events or significant increases in suicidal ideation were observed; the most common transient side effect was mild post-dosing headache.
• Structured Dosing & Therapy Protocol: The 11-week trial framework integrated 8 hours of preparatory psychotherapy, two synthetic psilocybin administration sessions (15 mg followed by 25 mg), and 6 to 8 hours of post-dosing integration therapy.
• Synergistic Catalyst Mechanism: Quantitative tracking revealed measurable symptom reductions during prep therapy alone, with massive acceleration following psilocybin administration, supporting the model that psilocybin acts as a pharmacological catalyst for deep psychotherapeutic processing.

Source: Ohio State University

The first U.S. clinical trial of psilocybin-assisted therapy in veterans with PTSD who got no relief from conventional treatments has established that the protocol is safe, causing no serious adverse events or increases in suicidal thinking or behavior.

But the preliminary clinical results exceeded researchers’ expectations: In the pilot trial with 12 veterans, 75% of participants were in remission one month after the study’s end. Their symptoms no longer met the criteria for post-traumatic stress disorder.

“For a population with severe treatment-resistant PTSD, these results are striking,” said Stacey Armstrong, first author of the new study, published today (July 30, 2026) in Communications Medicine.

“While treatments do work for some veterans with PTSD, they’re falling short for many, leaving veterans to continue to search for solutions, which can lead to treatment dropout, long-term disability and elevated suicide risk,” said Armstrong, senior researcher and associate director of the Center for Psychedelic Drug Research and Education (CPDRE) in The Ohio State University College of Social Work.

“It’s this unmet need that inspires us.”

The 11-week trial period combined eight hours of psychotherapy followed by two doses, 15 milligrams and 25 milligrams, of synthetic psilocybin, the active ingredient in magic mushrooms. Six to eight more hours of integrative therapy followed the drug treatment.

From baseline to one month after treatment was finished, there was an overall average drop of 27.5 points in clinician-rated PTSD symptoms among the group. Nine participants had a clinical response to treatment and were in remission. No severe adverse events occurred, with the most common side effect being a mild headache after taking psilocybin. Suicidal ideation scores did not significantly change from baseline to one month post-treatment.

Future papers from this study will assess the treatment’s effectiveness up to six months after the trial, as well as biological changes and effects on other PTSD-related problems like sleep disorders and substance use, said Alan Davis, senior author of the study, director of the CPDRE and associate professor of social work at Ohio State.

Anecdotal observations, and previous research showing that depression remission endured for five years after an earlier psilocybin trial that Davis co-led, suggest the combined therapies could have staying power for many people whose symptoms are not eased by traditional therapies.

“It’s been an incredible honor to work with veterans in this study, many of whom have been suffering with PTSD for decades or longer,” said Davis, who also holds faculty appointments in psychology and internal medicine at Ohio State.

“Some experiences we’ve seen in actual treatment sessions are extremely profound and meaningful. The ability for them to go back and to revisit really difficult events that happened to them and to find a new way of understanding them and a new way of moving forward in their life has really been exciting.”

One participant’s experience

To be eligible for the trial, veterans had to have severe PTSD that was considered treatment-resistant. The need for help in this population became quite evident as participant recruitment began: Over 3,600 applicants reached out to partake in online prescreening and 668 were assessed for eligibility. Though the initial goal was 15 participants, the final number was 12 – nine men and three women.

Zachariah Collett, a U.S. Army veteran from Washington Court House, Ohio, considers himself one of the lucky ones who was selected to participate.

Collett joined the Army in 2002 as an enlisted soldier and later became a military police corps paratrooper, serving a 28-month combat tour in Iraq. By age 25 he was medically retired. Among the diagnoses and service-connected disabilities that led to retirement was post-traumatic stress disorder.  

His symptoms included nightmares, a short temper, feeling constantly on guard and being angry virtually all the time – leading to behavior that had a negative effect on his family.

“I was just absolutely tortured by the internal struggle, the internal dialogue, the noise inside my head and the inability even to just be still,” Collett said. Years of trying counseling and medications didn’t help.

It was an intensive 41-day self-discovery experience combining a healthful diet with a series of integrative therapies that first put Collett on the path to healing. When he later learned about the psilocybin trial, he saw it as the perfect opportunity – and medicine – to take a “deeper dive.”

Now three years out from the treatment, he said the psilocybin-assisted therapy had a profound effect on him, his family and his marriage.

“For the first six months to a year, I felt like I had this fantastic set of training wheels while I’m relearning the way to act in situations,” he said. “That’s the great thing about this medicine. It’s gentle and it allowed me the space to rediscover, or discover, things I didn’t know I was capable of doing.

“It allowed me the opportunity to create peace, and stillness, and acceptance, and forgiveness and grace – all those things opposite of resentment and anger and hatred. It’s rather beautiful.”

Where the magic happens

A rigorous psychotherapy schedule is a key part of the process, with evidence from the trial suggesting that PTSD symptoms were lowered even before the drug was administered.

“There is this big question in the psychedelic therapy field right now about how much of this is a drug effect, how much of this is a therapy effect, and how much is a combination of the two,” Davis said.

This study, the first to try to answer the question, found a drop in PTSD symptoms from baseline to the end of preparation therapy, with a much larger reduction after the psilocybin doses.

“This treatment is more than just a drug,” Davis said. “The drug itself is a catalyst for the deep work that opens a window for people to perhaps access things they wouldn’t be able to access emotionally otherwise, and what that does is catalyze the therapeutic process after.

“That’s where the magic actually happens. It happens in the therapy, and in the changes that people start to make in their lives after the treatment’s concluded.”

The research team acknowledges that pilot studies with no control group tend to produce larger effect sizes than standard clinical trials. They hope to secure funding to follow up with a larger randomized, controlled clinical trial.

“Recognizing the tools that we have don’t work so well and recognizing the significant burden of PTSD in the United States carried by our servicemen and women and veterans, this seemed like the right direction to go,” Armstrong said. “Too many veterans right now are suffering despite the treatments that we have, and that’s why we feel that this research is important.”

Davis, who has been studying psychedelics as a component of mental health treatment for the past 16 years, said, “This is a very exciting time for psychedelic-assisted therapy research. These treatments are generally safe, well tolerated and showing a strong signal of efficacy.”

Funding: This research was supported by Ohio State’s College of Social Work, The Center for Psychedelic Drug Research and Education, the Clinical Research Center/Center for Clinical Research Management of The Ohio State University Wexner Medical Center and Ohio State’s College of Medicine.

Additional co-authors were Adam Levin, Nathan Sepeda, Hillary Shaub, Taweh Hunter, Angela Douglas and Rafaelle Lancelotta, all of Ohio State.

Key Questions Answered:

Q: How severe was the PTSD among veterans enrolled in this pilot trial?

A: Enrolled veterans suffered from severe, service-connected PTSD that was explicitly categorized as treatment-resistant, meaning years of conventional counseling and psychiatric medications had failed to provide meaningful clinical relief.

Q: What is the relative contribution of the drug versus the therapy in psilocybin-assisted treatment?

A: Trial data showed that while preparatory psychotherapy produced measurable initial symptom reductions, psilocybin administration caused a dramatically larger reduction. The drug serves as a biological catalyst that temporarily opens an emotional window, enabling veterans to process traumatic memories during subsequent integration therapy.

Q: What are the next research steps planned for this treatment protocol?

A: The research team is conducting longitudinal follow-ups to evaluate symptom durability up to six months post-trial, alongside biomarker analyses assessing sleep and substance use. Funding is also being pursued for a larger randomized, double-blind, placebo-controlled clinical trial.

Editorial Notes:

• This article was edited by a Neuroscience News editor.
• Journal paper reviewed in full.
• Additional context added by our staff.

About this PTSD and psychopharmacology research news

Author: Emily Caldwell
Source: Ohio State University
Contact: Emily Caldwell – Ohio State University
Image: The image is credited to Neuroscience News

Original Research: Open access.
“Safety, Feasibility, and Preliminary Clinical Outcomes of Psilocybin-Assisted Therapy for Veterans with Treatment-Resistant PTSD: A phase 2 non-randomized clinical trial” by Stacey Armstrong, Adam Levin, Nathan Sepeda, Hillary Shaub, Taweh Hunter, Angela Douglas, Rafaelle Lancelotta, Alan Davis. Communications Medicine
DOI:10.1038/s43856-026-01767-4

Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex

 

Of course your competent? doctor ignored all the previous positive research on psilocybin for stroke! Over a decade of incompetence!

psilocybin (56 posts to May 2014)

Since there is a 23% chance of stroke survivors getting PTSD what is your doctor's treatment plan?

Harnessing Psilocybin to Treat PTSD

Treating PTSD With Ecstasy? You Might Have Some Questions. May 2018

Ecstasy Was Just Labelled a 'Breakthrough Therapy' For PTSD by The FDA August 2017

But this negative action:

FDA Rejects MDMA-Assisted Therapy for PTSD

The latest here:

Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex

Yingjie Du, Xiangting Zhao, […], and Liming Zhang https://orcid.org/0000-0002-9071-8985 zhanglm0308@163.com+3View all authors and affiliations

Abstract

Background:

 Posttraumatic stress disorder (PTSD) and major depressive disorder are often comorbid in humans. Psilocybin reportedly has beneficial therapeutic effects on depression, possibly by promoting neuroplasticity. PTSD is associated with the dysregulation of neuroplasticity in the hippocampus and medial prefrontal cortex (mPFC). We hypothesized that psilocybin might reduce fear memory by promoting neuroplasticity in the hippocampus and mPFC.

 We investigated the effects of psilocybin on fear memory and explored its underlying mechanisms. We generated a mouse model of PTSD via auditory-cued fear conditioning and treated the mice with either vehicle or psilocybin (2.5 mg/kg, intraperitoneal) on day 0. Fear memory was assessed by the percentage of freezing time in response to conditioned stimuli. Fear memory tests were conducted on days 1, 6, and 7, after which the mice were sacrificed. To investigate the role of neuroplasticity in mediating the effects of psilocybin on fear memory, we assessed structural neuroplasticity and neuroplasticity-associated marker protein levels in the hippocampus and mPFC 7 days after a single dose of psilocybin.

Results:

Psilocybin reduced the cue-induced fear response on days 1, 6, and 7. Psilocybin ameliorated the fear conditioning-induced decreases in neuroplasticity in the hippocampus and mPFC. Through Golgi-Cox staining, Western blotting, and immunofluorescence staining, we found that psilocybin increased dendritic branches and spine density, upregulated GluR1 and synapsin-1, enhanced brain-derived neurotrophic factor and mammalian target of rapamycin signaling, and promoted neurogenesis.

Conclusions:

A single dose of psilocybin reduces both the rapid and sustained fear memory in mice, at least in part by restoring neuroplasticity in the hippocampus and mPFC. These findings indicate that psilocybin has significant potential for use in the treatment of PTSD and other mental disorders characterized by fear memory.

Get full access to this article

Psychedelics Remodel Myelin to Heal PTSD

 Your competent? doctor is already prescribing psychedelics, right?

DMT (8 posts to November 2020)

ecstasy (19 posts to November 2012)

LSD (5 posts to September 2018)

CerAxon (5 posts to January 2012)

citicoline (15 posts to October 2011)

magic mushrooms (10 posts to October 2014) 

psilocybin (14 posts to May 2014)

Psychedelics (25 posts to August 2018)

And knows of the need for myelin repair post stroke!

myelin (79 posts to April 2011)

myelin regeneration (3 posts to August 2024)

myelin repair (5 posts to January 2025)

And knows all about preventing and fixing your PTSD!

Since there is a 23% chance of stroke survivors getting PTSD what is your doctor's treatment plan?

OH NO, your doctor is incompetent in all points! What will you do to correct that problem?

Psychedelics Remodel Myelin to Heal PTSD

Summary: For years, scientists have focused on how psychedelics “rewire” neurons. But a groundbreaking study has found a “missing link” in long-term PTSD recovery: myelin remodeling. Researchers discovered that psilocybin and MDMA do more than just alter brain activity; they trigger the physical repair of myelin—the insulating layer that protects nerve fibers and synchronizes brain signals.

By “re-insulating” the circuits that have been frayed by trauma, these drugs help harmonize the rhythm of brain networks, turning a temporary “psychedelic window” into a permanent structural recovery.

Key Facts

• The “Missing Link”: While psychedelics provide rapid relief, long-term stability requires circuit-level repair. This study identifies adaptive myelination as the key to sustaining those benefits.
• Brain Synchronization: Myelin acts as the brain’s insulation. Remodeling this layer allows disrupted brain circuits (common in PTSD) to synchronize and harmonize their electrical rhythms again.
• Mechanistic Proof: Researchers used a rat model to show that blocking myelin repair prevented the long-term anti-anxiety effects of psilocybin and MDMA, proving that structural repair is necessary for recovery.
• Oligodendrocytes Matter: The study shifts the focus from neurons to oligodendrocytes—the cells that produce myelin—as the “gatekeepers” of long-lasting psychedelic healing.
• Anti-Inflammatory Effects: In addition to repairing insulation, both drugs were found to reduce astrocyte reactivity, lowering brain inflammation associated with chronic stress.

Source: Elsevier

Post-traumatic stress disorder (PTSD) is not only characterized by strongly encoded traumatic memories, but also by disrupted coordination across brain networks.

New research shows that treatment with psychedelic drugs triggers a large-scale reconfiguration of brain network dynamics driven by the remodeling of myelin—the neuronal insulation layer.

The findings from the novel study in Biological Psychiatry show enhancing myelination might be a viable strategy to augment or sustain the therapeutic effects of psychedelic-assisted treatments for PTSD and related disorders.

Psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) produce rapid clinical effects in patients with PTSD. However, durable benefits require circuit-level stabilization.

As the underlying cellular mechanisms remain incompletely understood, the current study identifies myelin as the missing link bridging the short-lived psychedelic experience and longer-term maintenance of healthier neural network dynamics.

The study shows that activity-dependent oligodendrogenesis and myelin remodeling can tune the disrupted timing and persistent response to threat observed in PTSD by synchronizing and harmonizing the rhythm of brain circuits.

John Krystal, MD, Editor of Biological Psychiatry, explains, “The focus of psychedelic and MDMA research has been the effects of these drugs on neurons and neuroplasticity. This work has largely ignored a potentially important role for other cell types in the neurobiology of their therapeutic effects.

“Oligodendrocytes play a number of roles in the brain, which produce the myelin that insulates neurons. Subgroups of oligodendrocytes take up glutamate and contribute to glutamate homeostasis, protecting the brain from neurotoxicity. Another group of oligodendrocytes is involved in immune and inflammatory functions in the brain.”

Researchers used a rat model of contextual fear conditioning and administered repeated low doses of psilocybin or MDMA. They then quantified anxiety-like and exploration behaviors and assessed spatial learning and memory.

The results showed that anxiety-like behaviors were reduced—a shift accompanied by changes in oligodendrocyte biology and multi-omic (genetic) signatures towards myelin remodeling in the dentate gyrus (part of the hippocampus, the brain’s memory center).

“To test whether myelin integrity was simply associated with behavioral change—or actually required for it—we combined the drug interventions with models that either damaged brain insulation (demyelination) or chemically enhanced it (promyelination) to see how these changes affected recovery,” explains lead investigator Mehmet Bostancıklıoğlu, PhD, Department of Physiology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey.

Using high-powered microscopy and genetic analysis, the researchers confirmed both psilocybin and MDMA trigger physical myelin repair. Furthermore, a serotonin receptor 5-HT_2A blockade prevented both the behavioral and myelin-associated effects.

When the team used a different drug (anisomycin) to block the formation of fear memories, anxiety decreased, but the myelin remained unrepaired. This suggests that while memories can be suppressed, biological recovery requires the structural support of myelin.

“Taken together, this moves oligodendrocytes and adaptive myelination from ‘background correlates’ to a mechanistically testable gate on the durability of psychedelic-associated circuit change,” notes Dr. Bostancıklıoğlu.

“The implication of oligodendrocytes in the therapeutic effects of psychedelics and MDMA is important because of their many functions in the brain, including myelin formation, glutamate homeostasis, and neuroinflammation. The dependency of the therapeutic effects of these drugs in animals may suggest that myelin compromise may undermine their efficacy,” adds Dr. Krystal.

“Overall, these data suggest that psychedelics and MDMA, like selective serotonin reuptake inhibitors (SSRIs) and ketamine, may promote the recovery from stress-related damage to myelin, contributing to clinical recovery.”

The study also found that psilocybin and MDMA reduce astrocyte reactivity that can cause inflammation.

The investigators point out that enhancing myelination would not be expected to replace psychotherapy; rather, it could support consolidation and maintenance of healthier network communication after the acute psychedelic session, when the brain is transitioning from destabilization back towards reintegration.

Dr. Bostancıklıoğlu concludes, “We often talk about psychedelics as ‘opening a window’ for brain plasticity. Recent work emphasizes that these drugs can acutely loosen entrenched network patterns and then leave a sub-acute period in which experience can reshape circuits.

“What we show here is that myelin-producing cells may be an underappreciated part of that story—helping translate a transient window into longer-lasting circuit change, at least in a fear-based rat model.”

Key Questions Answered:

Q: Do psychedelics just “mask” traumatic memories?

A: No—this study shows they actually help fix the wiring. Trauma “frays” the insulation (myelin) of your brain’s communication lines, leading to static and mistimed signals. Psychedelics like psilocybin and MDMA trigger the brain to physically re-wrap those wires, allowing for clearer, calmer communication.

Q: Why is “neural insulation” so important for PTSD?

A: In PTSD, the brain’s fear circuits are often “over-active” and poorly timed. Myelin ensures that signals travel at the right speed. By repairing this insulation, the brain can better synchronize its networks, helping to “turn down the volume” on persistent threat responses.

Q: Does this mean I can just take psilocybin and be cured?

A: Not quite. The researchers emphasize that these drugs “open a window” of plasticity. The physical repair of myelin provides the structural support needed for that window to stay open, but it works best alongside therapy to reintegrate those healthier network patterns.

Editorial Notes:

• This article was edited by a Neuroscience News editor.
• Journal paper reviewed in full.
• Additional context added by our staff.

About this PTSD and psychedelics research news

Author: Eileen Leahy
Source: Elsevier
Contact: Eileen Leahy – Elsevier
Image: The image is credited to Neuroscience News

Original Research: Open access.
“MDMA and Psilocybin Regulate Oligodendrocyte-Lineage Cell Numbers and Anxiety-Like Behaviors in a Rat Model of Fear” by Mehmet Bostancıklıoğlu, Davut Sinan Kaplan, Ramazan Bal, Elif Yiğit, Hasan Ulusal, and Ebru Temiz. Biological Psychiatry
DOI:10.1016/j.biopsych.2026.01.016

Psychedelics may rewire the brain to treat PTSD. Scientists are finally beginning to understand how.

 Your doctors don't understand neuroplasticity either yet want you to use it for recovery. Hasn't your competent doctor been treating your PTSD with psychedlics for years now? 

Psychedelics (25 posts to August 2018)

Since there is a 23% chance of stroke survivors getting PTSD what is your doctor's treatment plan?

Harnessing Psilocybin to Treat PTSD

Treating PTSD With Ecstasy? You Might Have Some Questions. May 2018

Ecstasy Was Just Labelled a 'Breakthrough Therapy' For PTSD by The FDA August 2017

But this negative action:

FDA Rejects MDMA-Assisted Therapy for PTSD

The latest here:

Psychedelics may rewire the brain to treat PTSD. Scientists are finally beginning to understand how.

Lynnette Averill, the quest to find a treatment for post-traumatic stress disorder (PTSD) is deeply personal. Averill's father served as an enlisted infantryman with the U.S. Marine Corps in Vietnam and struggled to cope with his war experiences when he returned home. After years of ineffective treatments, he died by suicide when Averill was three.Driven by a mission to support veterans' mental health, Averill trained as a psychologist and began working with people with PTSD — a condition that affects more than 12 million Americans in any given year. Victims of violence, abuse and accidents can experience post-traumatic symptoms such as persistent flashbacks, hypervigilance, and entrenched negative beliefs about themselves and their environment. "People can be very stuck in black-and-white thinking, such as, 'I'm a bad person,' 'I deserve this,' 'the world is dangerous," Averill, a clinical research psychologist at the Baylor College of Medicine in Texas, said during a panel discussion at the Psychedelic Science conference in Denver in June 2025. Lynette Averill at a press event advocating for approving psychedelic drugs for therapeutic treatment of PTSD in veterans. She believes these drugs may have lifesaving potential.Science Spotlight takes a deeper look at emerging science and gives you, our readers, the perspective you need on these advances. Our stories highlight trends in different fields, how new research is changing old ideas, and how the picture of the world we live in is being transformed thanks to science. The root of these symptoms lie in how trauma shapes changes in the brain in the weeks and months after a frightening event. The brain's fear center — the amygdala — becomes hyperactive, constantly signaling danger, while the brain regions responsible for contextualizing memories and managing emotional responses become less active and less able to counterbalance those fear signals. Traditional therapies, such as antidepressant medications and trauma-focused psychotherapies, help only a fraction of patients and can take months to be effective. "For many people with PTSD, they simply aren't enough, " Averill told Live Science. Consequently, Averill is one of a group of researchers who are exploring a new potential avenue for treating PTSD: psychedelics. Psychedelic-assisted psychotherapy, using MDMA or psilocybin, may act on the brain systems disrupted in PTSD, rather than simply treating the symptoms. The early findings have been positive: A recent clinical trial showed that 67% of patients who received MDMA-assisted therapy no longer met PTSD criteria after treatment, compared with 32% in the placebo group, and clinical trials investigating psilocybin's potential to treat the condition are showing promise Averill is currently leading a pioneering Texas state-funded clinical trial investigating psilocybin for veterans with PTSD and has seen how quickly the drugs can act. "There's potential for people to feel that the needle has moved in hours," Averill said. "And that is just quite literally lifesaving." How trauma changes the brain PTSD shares symptoms with depression and anxiety. Yet it is characterized by a response to a single trauma or set of traumatic events. Such experiences spark fear and often challenge an individual's core beliefs that the world is a just, safe and predictable place. People with PTSD can feel helpless and without agency. It's normal for people who have endured traumatic events to experience these symptoms for a short time, and for most people, they resolve within a week or two, clinical psychologist Gregory Fonzo, a co-director of the Charmaine and Gordon McGill Center for Psychedelic Research and Therapy at the University of Texas at Austin's Dell Medical School, told Live Science. But a subset of people get stuck. "PTSD is essentially a disorder of nonrecovery," Fonzo said. During the instigating event, trauma activates the brain's fear alarm system, including the amygdala, and signals a rapid release of stress hormones and neurotransmitters, such as norepinephrine (noradrenaline). The higher levels of norepinephrine increase arousal and the physiological “fight or flight” response. The interaction of norepinephrine and corticotropin-releasing hormone modulates increases activity between the amygdala and hippocampus, reinforcing the synaptic connections that help store fear and vivid details of the event. For the majority of people who recover quickly, this powerful fear response is successfully extinguished. The prefrontal cortex, the brain's regulatory control system, and the hippocampus, the brain's center for memory, exert top-down control and file the event as a past memory and no longer dangerous, which restores normal signaling in the amygdala. For people who develop PTSD, however, the trauma creates more persistent changes in the brain, Dr. Jerrold Rosenbaum, a psychiatrist and director of the Center for Neuroscience of Psychedelics at Massachusetts General Hospital, told Live Science. A 3D MRI reveals the limbic system (outlined in red), which plays a key role in PTSD. PTSD sufferers often have differences in the amygdala (awalnut-size region at the center of the brain) and the hippocampus, a seahorse-shaped region below that. In PTSD, the amygdala remains stuck in an overactive state, causing symptoms like hyperarousal, irritability and being easily startled. At the same time, the prefrontal cortex, which normally calms those alarms, becomes underactive, leaving the amygdala's overreactive fear response unchecked. Neuroimaging has shown that PTSD is associated with a reduced volume of the hippocampus, which is the brain region that processes the context — the where, when and circumstances — of an event. In normal circumstances the hippocampus can discriminate between real and perceived danger. For example, it will categorize the sound of a car backfiring in an everyday environment differently than the blast of gunshot, which occurred specifically in a war zone. But a diminished hippocampus could make it harder for patients to distinguish between the two.Changes in the connectivity of the default mode network(DMN), a set of interconnected brain regions that are highly active when a person is resting, their mind is wandering, or they are engaged in thinking about themselves or their memories rather than the outside world. Researchers hypothesize that heightened connectivity within the DMN is a neurobiological abnormality that pushes the system into overdrive, potentially leading to rumination or the involuntary re-experiencing of negative events(or flashbacks), which are characteristic symptoms of PTSD. In PTSD, the DMN also appears to be abnormally disconnected from the executive control regions and simultaneously abnormally connected with lower-level emotional systems, such as the amygdala. Scientists believe this increased coupling may drive intense, automatic emotions such as shame and guilt. In a healthy brain, the prefrontal cortex can evaluate and change upsetting thoughts, but PTSD compromises this ability. PTSD is also associated with reduced levels of brain-derived neurotrophic factor(BDNF), a signaling protein that is critical for neural plasticity — the formation of new synapses and the strengthening or pruning of existing neural connections. The deficit in BDNF effectively "locks" the trauma response in place and can prevent the brain from integrating new, non-fearful thinking, scientists theorize. "PTSD can definitely manifest in rigidity and entrenchment of ways of thinking about oneself and others in the world,Brandon Weiss, a psychologist at the Johns Hopkins Medical Center for Psychedelic and Consciousness Research, told Live Science. Treatment challenges Physicians have used trauma-focused psychotherapy, such as cognitive processing therapy (CPT) and prolonged exposure (PE), to treat PTSD. In CPT, therapists guide patients to examine and change distorted thinking, such as the belief that they are to blame for events outside of their control. PE focuses on teaching the patient to reduce their fear by gradually confronting the traumatic memories in a controlled environment. But these treatments are difficult for people to go through because they have to face the stuff that is really bothering them, Fonzo said. "So a lot of people drop out before they finish the treatment." Access to specialized, trauma-focused therapists can be challenging, and not everyone benefits from such treatments, Fonzo said. Other treatment options include SSRIs, like sertraline (Zoloft) or paroxetine (Paxel), but only 20% to 30% of patients experience a remission on these drugs.  Most importantly, many patients feel like the medication hasn't addressed the root cause of their trauma, Rosenbaum said.

Creating a safe space to process trauma

For Jennifer Mitchell, a neuroscientist and the associate chief of staff for research and development at San Francisco Veterans Affairs Medical Center, it was imperative to find effective treatments for military veterans suffering from PTSD.

"I see how debilitating it is for individuals that have served and have experienced combat," Mitchell told Live Science. "And we absolutely owe them to come up with better treatments."

Nearly a decade ago, Mitchell and her colleagues began to investigate whether MDMA (3,4-methylenedioxymethamphetamine), commonly known as ecstasy or molly, could treat PTSD when used in conjunction with psychotherapy. In 2023, the team published their findings on a diverse group of 104 participants with PTSD from the general population, 80% of whom had a history of contemplating suicide. By the end of the study, 71% of the participants who'd received MDMA no longer met the criteria for PTSD, and another 15% still had symptoms but had what the researchers termed a "clinically meaningful benefit."

A computer rendering of the molecular structure of MDMA. Early research suggests MDMA can help patients with PTSD recover from the disease. (Image credit: PROF. K.SEDDON & DR. T.EVANS, QUEEN'S UNIVERSITY BELFAST / SCIENCE PHOTO LIBRARY)

MDMA's effectiveness hinges partly on its ability to act as a neuroplastogen — a compound that harnesses the brain's ability to form new connections and strengthen and reorganize existing connections. In the past few years, scientists have begun to explore the potential for another neuroplastogen to treat PTSD: psilocybin.

Clinical trials have found psilocybin, the main psychoactive ingredient in magic mushrooms, to be a promising therapy for treatment-resistant anxiety and depression, and studies conducted on animals have pointed to its potential for treating PTSD.

A study on mature adult mice demonstrated that MDMA temporarily reopens a critical period for where the brain is sensitive to learning that social behaviors are beneficial by inducing structural and functional changes in the brain’s reward circuits. Specifically the drug makes the nucleus accumbens reward circuitry more sensitive to the social hormone oxytocin. This enhanced sensitivity allows the adult brain to re-encode social cues as intrinsically rewarding and safe, facilitating the re-learning of trust and attachment for up to two weeks after a single dose, the researcher theorize.

Mitchell has witnessed similar responses in humans and hypothesizes that the drug creates a neurobiological state in which patients can form a strong, trusting bond with a therapist. "There's a therapeutic window where people feel renewed energy, they don't feel so stuck, and they can actually work on the psychological side of their issues," Mitchell said.

Simultaneously, functional neuroimaging data points to MDMA's impacts on the fear circuitry of the brain. The drug decreases activity in the amygdala while increasing activity in the prefrontal cortex. MDMA also restores normal levels of BDNF in the amygdala, hippocampus and prefrontal cortex, theoretically leading to the formation of new synapses and structural changes that enable greater plasticity in these regions.

Researchers hypothesize that the dampening of the fear response, the enhancement of the prefrontal cortex's regulatory role, and the restoration of flexibility in key brain regions set the scene for patients to revisit and reprocess memories without being overwhelmed by fear. By entering therapy with this more regulated perspective, recovery can happen quickly.

"By the end of a treatment session, you can see that something has shifted. The subject will be holding themselves differently and look hopeful," Mitchell said. "I've been doing this type of research for 35 years, and it is the most remarkable thing that I've seen."

Once the patients have analyzed and processed their trauma, they are less likely to slip back into their PTSD symptoms after MDMA, Mitchell said. The researchers collected data on the patients in increments over the two years after their treatment ended, and the positive benefits appear to be durable, Mitchell said.

Breaking free

When a single dose of psilocybin was injected into chronically stressed mice that had developed learned helplessness and avoidance behaviors, for example, researchers could see immediate and enduring structural changes in the rodents' brains. The rapid increase in dendritic spines — the tiny protrusions that form synapses, the connections between brain cells —suggests that psilocybin may directly reverse the loss of neuronal connections observed in the frontal cortex of rodents subjected to chronic stress, the authors suggest. And the changes could prepare the brain for fear extinction and emotional processing —key elements of overcoming trauma.

Consequently, several trials are underway to investigate psilocybin as a treatment option for PTSD. In August 2025, biotechnology company Compass Pathways published its findings on a trial designed to test the safety of psilocybin for PTSD. The small safety study wasn't designed to measure effectiveness. Nevertheless, participants seemed to show an immediate reduction in PTSD symptoms after a single 25-milligram dose of the company's synthetic psilocybin. Clinicians reported the improvements had endured when tested 12 weeks later.

In the study Averill is leading, clinicians started dosing seven participants who had experienced PTSD symptoms for an average of 19 years at the start of the trial in February. The early findings "have been incredible," Averill said during a panel discussion at the Psychedelic Science conference in Denver in June 2025.

Psilocybin is the active ingredient in "magic mushrooms." Research in animals suggests that the psychedelic substance may help erase fear memories and reduce neuronal loss in sensitive brain regions. (Image credit: KATERYNA KON / SCIENCE PHOTO LIBRARY)

Within a few hours of the first dose of psilocybin, every single veteran reported positive changes in their beliefs and perceptions. After the treatment effects subsided, participants underwent therapy and said the drug enabled them to reevaluate their original traumatic experiences from a nonjudgmental perspective, without the shame and guilt, Averill said.

So how does psilocybin bring about these changes?

Studies in mice have demonstrated that, in a similar vein to MDMA, psilocybin helps brain cells grow new dendritic spines. These new branches appear in the prefrontal cortex and the hippocampus, the key regions responsible for learning, planning and memory.

But brain scans from people have shown that psilocybin simultaneously disrupts and desynchronizes, or dissolves, connectivity within the DMN for three weeks. Scientists hypothesize that this desynchronization of the brain system involved in self-referential processing results in a mind that is less constrained, more flexible and less consumed by self-reproach. They propose that the disruption of rigid cognitive patterns and negative thought loops may promote psychological flexibility and self-compassion.

"It has been surprising to see these maladaptive beliefs shift when I'd learned that change would only come about through longer term talk therapy," Weiss said.

Dissolving rigid thinking can open up the mind to new possibilities, including the idea that the patient wasn't responsible for the original trauma, Weiss said. Weiss is currently carrying out a clinical trial examining the effect of psilocybin therapy on the cognitive beliefs related to PTSD and is witnessing participants' experiences of the treatment.

"Many are endorsing less guilt and are able to let go of the sense that they were to blame for this happening," he said.

Proceeding cautiously, with haste

When Fonzo first reviewed the data on psychedelics as a treatment option in mental health, he was excited by what he found. But he pointed out that there haven't yet been any large, controlled studies evaluating psilocybin for PTSD. The research is still in its early stages with small pilot studies or clinical trials still assessing the safety of the drug. "There needs to be a sober perspective on what the evidence does, and does not show," Fonzo said, "because these treatments aren't necessarily going to be suitable for everyone."

Fonzo believes the answer lies in the expansion of funding for clinical trials, but research in psychedelics still faces steep hurdles. Both MDMA and psilocybin are listed as Schedule I substances in the U.S. — a federal classification reserved for drugs considered to have a high potential for abuse and no accepted medical use. That label makes studying them a bureaucratic nightmare, as researchers must navigate complex regulatory approvals and secure special licenses just to handle the compounds.

On top of that, every trial demands careful screening to find participants who meet the strict inclusion and exclusion criteria. Also, due to the profound and unmistakable psychoactive effects of psychedelics, in trials, it can be hard to hide who is and isn't getting the drug and thus create a robust placebo group.

A homeless army veteran rests in a bed at a Homeless Services Center in Maine. Veterans often struggle with PTSD symptoms, and the current treatment options only help a fraction of those with the condition. (Image credit: Lane Turner/The Boston Globe via Getty Images)

Despite these challenges, new clinical trials are underway to explore variations in dosage, psychotherapy pairing and long-term outcomes. Weiss and his colleagues are investigating administering combinations of MDMA and psilocybin — so-called psychedelic stacking — and comparing the effectiveness of each treatment separately. "We're still learning about what is the most efficient and rapid-acting approach to helping people," Weiss said.

For veterans who are experiencing suicidal thoughts as part of their PTSD, finding interventions that spur rapid change could be key, Weiss said. Despite the compelling findings, the regulatory approval of psychedelic treatments for PTSD is moving slowly. In August 2024, the U.S. Food and Drug Administration declined to approve MDMA-assisted therapy for PTSD, citing concerns over the study design and blinding procedures. Mitchell has been frustrated about the decision not to approve the treatment with guardrails, or for a subset of people who really need it.

RELATED STORIES

—Psychedelic drug ayahuasca could treat PTSD, early studies hint. But exactly how it works isn't clear.

—When will MDMA be approved for therapy? Major trial issues may stand in the way, psychiatrist Dr. Albino Oliveira-Maia says.

—Traumatic memories are processed differently in PTSD

"My own brain gets cranky when I hear people not consider PTSD a life-threatening condition — because it is," Mitchell said. In the United States in 2024, an average of 17 veterans died each day by suicide.

"That's why speed matters. We can't wait months for treatments that barely work," Mitchell said.

Averill has witnessed PTSD patients liberated by psychedelic therapy, but she cautioned that the psychedelic experience is not a "silver bullet" but rather one that opens the doors to healing. One veteran in the clinical trial she'd been leading described feeling like he'd been locked in a cage and said every movement felt painful. The psilocybin removed the cage, and he was able to revisit his traumatic experiences.

Averill's goal is to continue exploring how psychedelic-assisted therapy can help PTSD sufferers move beyond merely tolerating their existence. "We want to help people move forward and build lives they really want to be living," Averill said.